HNSA — Hansa Biopharma AB Share News
0.000.00%
Last trade - 00:00- SEK4.77bn
- SEK4.38bn
- SEK222.27m
Sweden's Hansa Biopharma Q3 revenue surges on SERB license deal
Brief: Hansa Biopharma Q3 Net Income SEK -178.5 Million
Brief: Hansa Biopharma Announces Positive Idefirix Paes Results Presented In The High-Impact Clinical Trials Session At Asn Kidney Week
Brief: Hansa Biopharma Submits IND Application To FDA For HNSA-5487 In GBS
Brief: Hansa Biopharma Partners With Cradle To Advance AI-Driven Protein Design And Engineering
Brief: CEO Buys SEK 1.5 Mln Of Hansa Biopharma Shares
Brief: Devin Holden Divests SEK 1.4 Million Worth Of Hansa Biopharma Shares
Sweden's Hansa Biopharma Q2 revenue dips
Brief: Hansa Biopharma Q2 Net Income SEK -260.5 Million
Brief: Hansa Biopharma Signs Idefirix Licensing Deal With SERB For Europe, MENA
Brief: Hansa Biopharma Appoints Adam Cutler As New Chief Financial Officer
Brief: Hansa Biopharma Reports Positive Efficacy, Safety Results From Study
Brief: Serb Pharmaceuticals To Acquire European And MENA Rights To Idefirix From Hansa Biopharma
Sweden's Hansa Biopharma Q1 revenue drops 48% amid commercial reorganization in Europe
Brief: Hansa Biopharma Q1 Net Income SEK -196.3 Million
Brief: Hansa Biopharma Enters $30 Million Convertible Loan Agreement With Athyrium
Brief: Hansa Biopharma Says PDUFA Action Date For Imlifidase BLA Set For December 19, 2026
Brief: Hansa Biopharma Says Co's Biologics License Application (BLA) For Imlifidase Accepted By The FDA
Brief: Hansa Biopharma Board Proposes That No Dividend Will Be Paid For 2025